Key points are not available for this paper at this time.
The objective of this study was to evaluate the efficacy and safety of semaglutide 2.4 mg, a glucagon-like peptide-1 receptor agonist, by race and ethnicity, across three phase 3 trials.
Rubino et al. (2024) studied this question.